Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Pancreatic Neoplasms
Interventions: BAY86-9766+Gemcitabine; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Aurora, Colorado • Pittsfield, Massachusetts

Conditions: Obesity
Interventions: Intervention; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 9 Years to 100 Years
Enrollment: 890 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: SARS-CoV-2 Infection
Interventions: Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma); Biological
Lead sponsor: Max O'Donnell; Other
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Foot Ulcers
Interventions: DermaPure™, Standard care; Other
Lead sponsor: TRx Wound Care Limited; Industry
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Miami, Florida • New York, New York + 3 more

Conditions: Drug Interactions
Interventions: Fexofenadine, Telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neoplasms, Head and Neck
Interventions: Lapatinib, Chemoradiation, Placebo; Drug · Radiation · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more

Conditions: Advanced Hepatocellular Carcinoma
Interventions: INC280, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Kansas City, Missouri

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 545
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more

Conditions: Blood Loss, Surgical, Postoperative Hemorrhage
Interventions: Trasylol (Aprotinin, BAYA0128), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more

Conditions: Kidney Diseases, Kidney Injury, Kidney Failure
Interventions: MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR); Drug · Device
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more

Conditions: Primary Immunodeficiency
Interventions: IGIV-C 10%, IGSC 20%; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more

Conditions: Head and Neck Cancer
Interventions: Therapy for head and neck cancer; Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 26,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Minnetonka, Minnesota

Conditions: Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions: NBF-006; Drug
Lead sponsor: Nitto BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 9
States / cities: Beverly Hills, California • La Jolla, California • Tampa, Florida + 6 more

Conditions: Coronavirus Disease 2019 COVID-19
Interventions: TJ003234, Placebo; Drug
Lead sponsor: I-Mab Biopharma US Limited; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 14
States / cities: Little Rock, Arkansas • Sylmar, California • Washington D.C., District of Columbia + 10 more

Conditions: Diabetic Foot Ulcers (DFUs)
Interventions: Antimicrobial agent; Drug
Lead sponsor: Lakewood-Amedex Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Doral, Florida • Margate, Florida + 3 more

Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions: Intravenous and Intranasal BMSC; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Pseudobulbar Affect (PBA)
Interventions: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 45
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more

Conditions: Acute Liver Failure, Hepatic Encephalopathy
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: Up to 18 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more

Conditions: Renal Transplantation
Interventions: tacrolimus, CellCept, steroids (methylprednisone or prednisone); Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 29
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more

Conditions: Sepsis
Interventions: Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more

Conditions: Tendinopathy
Interventions: SM04755, Vehicle; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 30
States / cities: Encinitas, California • Long Beach, California • Pasadena, California + 25 more

Conditions: Cardiovascular Disease, Diabetes, Metabolic Syndrome
Interventions: Regular Canola Oil, High Oleic Canola Oil, Western Type Diet - Common Dietary Oils; Other
Lead sponsor: University of Manitoba; Other
Eligibility: 20 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Acute Heart Failure
Interventions: RLX030, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 105
States / cities: Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more

Search by objective public record fields.

Combination With Gemcitabine in Advanced Pancreatic Cancer

B'More Healthy; Communities for Kids (BHCK)

Plasma Therapy of COVID-19 in Severely Ill Patients

A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Head and Neck Cancer Registry (LORHAN)

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU

Neurologic Stem Cell Treatment Study

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

Vitamin C, Thiamine, and Steroids in Sepsis

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Canola Oil Multi-Centre Intervention Trial II

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF